drugset / Trial / NCT00134134

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

NCT00134134

Phase 1 Completed 5 enrolled NYU Langone Health Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.

Timeline

Start
2005-02
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject efalizumab Monoclonal antibody Subcutaneous